Events over the last few years have foreshadowed a future where the research and translation of biomedical advances must anticipate the uncertain. Numerous developments – from climate change to globalization and political instability – paint a new reality, where ensuring that healthcare advances reach intended users means securing every step of the value chain in a rather unpredictable world.
At Roche CustomBiotech, we saw that clearly with the SARS-CoV-2 pandemic. As demand for our high-performance raw materials grew, we faced precisely that unpredictability. How much will be needed? Can we build out capacities to be responsive to fluctuations in requests but robust to bottlenecks in our own supply chain? Today, we have answers. Today, we are prepared.
Under the accelerated innovation pace to manage the pandemic, a commonly ignored family of reagents moved into the forefront: dNTPs.
Nucleotides are at the heart of any PCR-based assay but often neglected as a non-critical, low-cost component. However, given heightened competition in the biomedical and diagnostics markets, how will you secure a steady supply of dNTPs in the face of a new global emergency?
How will you keep short your path from development to deployment if you are forced to source your dNTPs from several, varying suppliers?
